MRNA
Moderna, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 16 GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC v…
- Jul 4 Trial readout: Results Pending: mRNA-1647 (Phase 2), Completed 53d ago
- Aug 5 ▼ 1 insider sell $28.7M at $57.52
- Aug 31 ▲ Short interest falls 25.9% to 39.15M
- Sep 1 ▼ 1 insider sell $485.8K at $139.95
- Sep 10 to Sep 15 ▼ 3 days of insider sells: $16.4M by 2 insiders, avg $141.90
- Sep 30 ▲ 10 funds open new positions (13F)
- Oct 13 to Oct 20 ▲ 2 buys: Ro Khanna, Gilbert Cisneros bought $1,001 - $15,000, last disclosed Nov 11
- Oct 14 to Oct 15 ▼ 2 days of insider sells: $17.0M by 1 insider, avg $217.10
- Oct 22 9 Reddit mentions, 21.0× the usual (bear crowd, insiders selling)
- Oct 27 ▼ William Blair downgrades
- Nov 6 ▲ Moderna reported Q3 2026 revenue of $1.313B (consensus $890.2M) and…
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $62.6M.
- InstitutionsBULLISH
Q3 2026: 76 added (10 new), 50 trimmed or exited. Largest new: Hrt Financial $351.3M, Connor, Clark & Lunn Investment Management $52.7M.
- AnalystsMIXED
10 of 31 rate it Buy or better.
- Short sellersSTEADY
Short interest +1.8% to 33.19M shares. 1.8 days to cover, ≈8.2% of shares.
- TrendUPTREND
6% above its 50-day average.
- SocialMIXED
Crowd 52° (neutral) this week from 26 mentions: 6 bullish, 5 bearish. No setup is alerting. Excludes 2 subscriber-only days.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BAILLIE GIFFORD & CO | TRIM | $2.2B |
| MORGAN STANLEY | TRIM | $1.2B |
| Qube Research & Technologies Ltd | DOUBLED | $562.9M |
| JPMORGAN CHASE & CO | DOUBLED | $525.8M |
| Invesco Ltd. | TRIM | $505.0M |
| HRT FINANCIAL LP | NEW | $351.3M |
| BARCLAYS PLC | TRIM | $126.3M |
| RHUMBLINE ADVISERS | TRIM | $105.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
31 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Goldman Sachs MAINTAIN | Neutral |
| Nov 9, 2026 | Piper Sandler REITERATE | Overweight |
| Oct 27, 2026 | William Blair DOWNGRADE | Market Perform |
| Oct 26, 2026 | Piper Sandler REITERATE | Overweight |
| Oct 21, 2026 | TD Cowen MAINTAIN | Hold |
| Oct 15, 2026 | Goldman Sachs MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Andres Juan Chief Operating Officer Nov 5, 2026 | AWARD | 7,898 sh |
Andres Juan Chief Operating Officer Nov 5, 2026 | AWARD | 16,955 sh |
Hoge Stephen President Oct 15, 2026 | SELL | $8.6M |
Hoge Stephen President Oct 15, 2026 | EXERCISE | $933.5K |
Hoge Stephen President Oct 14, 2026 | SELL | $8.3M |
Hoge Stephen President Oct 14, 2026 | SELL | $96.4K |
Hoge Stephen President Oct 14, 2026 | EXERCISE | $933.5K |
Mock James M Chief Financial Officer Oct 5, 2026 | TAX W/H | $133.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026| Oct 22, 2026 | Volatility Pause | Resumed |
Stocks flagged as Bearish crowd beat the market by 5.7% over the next month on average; 69% of 35 did better than the market. This setup is still being watched, so it takes no view yet.
SecBot reports
26 filings · 2 bullish · 7 bearish · 3 mixed · 14 neutral- NEUTRAL 144Nov 16, 2026
President Stephen Hoge filed a Form 144 notice to sell 39,160 shares of common stock, valued at approximately $8.6 million, through Fidelity Brokerage Services. The shares were acquired via stock option exercise on the same day.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 13, 2026
Moderna entered into a Transitional Services and Retirement Agreement with Chief Legal Officer…
Monitor for the appointment of a new Chief Legal Officer, which could signal strategic priorities. The Arbutus and Pfizer litigation outcomes are material to the contingent payments but the amounts…
- BULLISH 8-KNov 6, 2026
Moderna reported Q3 2026 revenue of $1.313B (consensus $890.2M) and GAAP diluted EPS of $0.38…
The significant revenue beat and raised guidance reflect strong execution on international COVID vaccine deliveries and cost discipline. Watch for the November 12 Analyst Day for further pipeline…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G for Moderna, reporting beneficial ownership of…
Fidelity's increased passive stake signals continued institutional confidence but no change in control intent. Monitor for any future conversion to a 13D filing, which would indicate activist…
All MRNA filing & press-release reports (26)
- 144 reportNov 16, 2026
- 8-K reportNov 13, 2026
- 8-K reportNov 6, 2026
- SC 13G/A reportNov 5, 2026
- INST-CLUSTER reportOct 28, 2026
- William Blair downgrades MRNA to Market PerformOct 27, 2026
- 8-K reportSep 30, 2026
- Citigroup downgrades MRNA to Sell, PT $80 (-60.7%)Sep 30, 2026
- CLUSTER reportSep 16, 2026
- Rothschild & Co double downgrades MRNA to Sell, PT $81 (-46.3%) from $40Sep 3, 2026
- COURT-RULING reportAug 31, 2026
- Wolfe Research upgrades MRNA to Peer Perform, PT $0 (N/A%)Aug 25, 2026
- William Blair upgrades MRNA to Outperform, PT $N/A (N/A%)Aug 19, 2026
- 144 reportAug 5, 2026
- 8-K reportJul 31, 2026
- 3 reportJul 10, 2026
- 8-K reportJul 8, 2026
- 144 reportJun 18, 2026
- COURT-RULING reportJun 16, 2026
- CLUSTER reportMay 22, 2026
- 144 reportMay 21, 2026
- 144 reportMay 8, 2026
- COURT-RULING reportMar 30, 2026
- DEFA14A reportMar 16, 2026
- 8-K reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026